Key facts
- Kytopen’s last known valuation is $47.0M (Sep 2024).
- It has raised $52.9M across 5 recorded rounds; the latest was Early Stage VC ($7.1M) in Feb 2025.
- Notable investors include US National Science Foundation, National Institutes of Health, Alexandria Venture Investments, The Engine, MassVentures — 16 tracked in total.
- Kytopen has filed 5 Form Ds with the SEC since 2019, most recently Feb 2025 ($7.1M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Kytopen
Funding rounds
5 roundsAbout Kytopen
Developer of a cell engineering platform designed to offer healthy and functional cells. The company's tool uses a fast, scalable, and gentle process that yields quality engineered cells in minutes while maintaining cell health and function, enabling researchers to combine continuous fluid flow with electric fields for efficient delivery of payloads to primary cells.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 26
- Website
- kytopen.com/
- Ownership
- Privately Held (backing)
Kytopen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kytopen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kytopen in its N-PORT filings yet. We sweep new filings monthly.